Probatebeta
Target

SSTR2

Somatostatin receptor type 2

As of the edition of 20 October 2026, SSTR2 (somatostatin receptor type 2, UniProt P30874) has 17 drugs tested at it and 24 companies on the list, 5 on route A and 8 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P30874
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
17
Disease areas
Cancer; Hormones; Digestive system; Nervous system; Bones, joints and muscles; Nutrition and metabolism; Urinary and reproductive; Inherited and neonatal
Registered trials of its drugs
419

Drugs at this target

StatusCount
Marketed8
Active1
Went quiet3
Stopped3
Withdrawn from market1
Status not established1
Total17
DrugStatusFurthest phaseUS protection
OctreotideMarketedPhase 4none listed
LanreotideMarketedPhase 4none listed
PasireotideMarketedPhase 4Ends 2026
Lutetium oxodotreotideMarketedPhase 4Ends 2031
SomatostatinMarketedPhase 4none listed
PaltusotineMarketedPhase 3Ends 2039
Copper oxodotreotideMarketedPhase 4Ends 2027
VeldoreotideWent quietPhase 2none listed
Indium pentetreotideMarketedPhase 4none listed
ONO-5788StoppedPhase 1none listed
OnzigolideStoppedPhase 2none listed
TidutamabStoppedPhase 2none listed

12 of 17 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B8
Engaged5
Undetermined6
Total on the list24
Three companies on route A or B, with the route only
CompanyRoute
IpsenRoute B
CuriumRoute B
Teijin PharmaRoute B

The other 21 companies at SSTR2

In the product

24 companies in all; 21 are not named here, and no score is.

See the 24 companies at SSTR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SSTR2

Other targets in cancer

Companies holding approvals at SSTR2